001     274081
005     20240229154925.0
024 7 _ |a 10.1186/s12916-023-02739-4
|2 doi
024 7 _ |a pmid:36855092
|2 pmid
024 7 _ |a altmetric:143004510
|2 altmetric
037 _ _ |a DKFZ-2023-00427
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Rothwell, Joseph A
|0 0000-0002-6927-3360
|b 0
245 _ _ |a Circulating amino acid levels and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition and UK Biobank cohorts.
260 _ _ |a Heidelberg [u.a.]
|c 2023
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1677769252_19618
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Amino acid metabolism is dysregulated in colorectal cancer patients; however, it is not clear whether pre-diagnostic levels of amino acids are associated with subsequent risk of colorectal cancer. We investigated circulating levels of amino acids in relation to colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) and UK Biobank cohorts.Concentrations of 13-21 amino acids were determined in baseline fasting plasma or serum samples in 654 incident colorectal cancer cases and 654 matched controls in EPIC. Amino acids associated with colorectal cancer risk following adjustment for the false discovery rate (FDR) were then tested for associations in the UK Biobank, for which measurements of 9 amino acids were available in 111,323 participants, of which 1221 were incident colorectal cancer cases.Histidine levels were inversely associated with colorectal cancer risk in EPIC (odds ratio [OR] 0.80 per standard deviation [SD], 95% confidence interval [CI] 0.69-0.92, FDR P-value=0.03) and in UK Biobank (HR 0.93 per SD, 95% CI 0.87-0.99, P-value=0.03). Glutamine levels were borderline inversely associated with colorectal cancer risk in EPIC (OR 0.85 per SD, 95% CI 0.75-0.97, FDR P-value=0.08) and similarly in UK Biobank (HR 0.95, 95% CI 0.89-1.01, P=0.09) In both cohorts, associations changed only minimally when cases diagnosed within 2 or 5 years of follow-up were excluded.Higher circulating levels of histidine were associated with a lower risk of colorectal cancer in two large prospective cohorts. Further research to ascertain the role of histidine metabolism and potentially that of glutamine in colorectal cancer development is warranted.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Amino acids
|2 Other
650 _ 7 |a Colorectal cancer
|2 Other
650 _ 7 |a Glutamine
|2 Other
650 _ 7 |a Histidine
|2 Other
650 _ 7 |a Amino Acids
|2 NLM Chemicals
650 _ 7 |a Glutamine
|0 0RH81L854J
|2 NLM Chemicals
650 _ 7 |a Histidine
|0 4QD397987E
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Amino Acids
|2 MeSH
650 _ 2 |a Glutamine
|2 MeSH
650 _ 2 |a Histidine
|2 MeSH
650 _ 2 |a Biological Specimen Banks
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Colorectal Neoplasms: epidemiology
|2 MeSH
650 _ 2 |a United Kingdom: epidemiology
|2 MeSH
700 1 _ |a Bešević, Jelena
|b 1
700 1 _ |a Dimou, Niki
|b 2
700 1 _ |a Breeur, Marie
|b 3
700 1 _ |a Murphy, Neil
|b 4
700 1 _ |a Jenab, Mazda
|b 5
700 1 _ |a Wedekind, Roland
|b 6
700 1 _ |a Viallon, Vivian
|b 7
700 1 _ |a Ferrari, Pietro
|b 8
700 1 _ |a Achaintre, David
|b 9
700 1 _ |a Gicquiau, Audrey
|b 10
700 1 _ |a Rinaldi, Sabina
|b 11
700 1 _ |a Scalbert, Augustin
|b 12
700 1 _ |a Huybrechts, Inge
|b 13
700 1 _ |a Prehn, Cornelia
|b 14
700 1 _ |a Adamski, Jerzy
|b 15
700 1 _ |a Cross, Amanda J
|b 16
700 1 _ |a Keun, Hector
|b 17
700 1 _ |a Chadeau-Hyam, Marc
|b 18
700 1 _ |a Boutron-Ruault, Marie-Christine
|b 19
700 1 _ |a Overvad, Kim
|b 20
700 1 _ |a Dahm, Christina C
|b 21
700 1 _ |a Nøst, Therese Haugdahl
|b 22
700 1 _ |a Sandanger, Torkjel M
|b 23
700 1 _ |a Skeie, Guri
|b 24
700 1 _ |a Zamora-Ros, Raul
|b 25
700 1 _ |a Tsilidis, Kostas K
|b 26
700 1 _ |a Eichelmann, Fabian
|b 27
700 1 _ |a Schulze, Matthias B
|b 28
700 1 _ |a van Guelpen, Bethany
|b 29
700 1 _ |a Vidman, Linda
|b 30
700 1 _ |a Sánchez, Maria-José
|b 31
700 1 _ |a Amiano, Pilar
|b 32
700 1 _ |a Ardanaz, Eva
|b 33
700 1 _ |a Smith-Byrne, Karl
|b 34
700 1 _ |a Travis, Ruth
|b 35
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 36
|u dkfz
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 37
|u dkfz
700 1 _ |a Derksen, Jeroen W G
|b 38
700 1 _ |a Colorado-Yohar, Sandra
|b 39
700 1 _ |a Tumino, Rosario
|b 40
700 1 _ |a Bueno-de-Mesquita, Bas
|b 41
700 1 _ |a Vineis, Paolo
|b 42
700 1 _ |a Palli, Domenico
|b 43
700 1 _ |a Pasanisi, Fabrizio
|b 44
700 1 _ |a Eriksen, Anne Kirstine
|b 45
700 1 _ |a Tjønneland, Anne
|b 46
700 1 _ |a Severi, Gianluca
|b 47
700 1 _ |a Gunter, Marc J
|b 48
773 _ _ |a 10.1186/s12916-023-02739-4
|g Vol. 21, no. 1, p. 80
|0 PERI:(DE-600)2131669-7
|n 1
|p 80
|t BMC medicine
|v 21
|y 2023
|x 1741-7015
909 C O |o oai:inrepo02.dkfz.de:274081
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 36
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 37
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-25
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-25
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-25
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BMC MED : 2022
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T09:07:15Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T09:07:15Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Open peer review
|d 2023-05-02T09:07:15Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-25
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BMC MED : 2022
|d 2023-10-25
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21